BioNTech
- Country
- 🇩🇪Germany
- Ownership
- Public
- Employees
- 6.1K
- Market Cap
- $20.7B
- Website
- http://www.biontech.de
- Introduction
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Clinical Trials
112
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (107 trials with phase data)• Click on a phase to view related trials
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 420
- Registration Number
- NCT07111520
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: SoC chemotherapy treatment 1Drug: SoC chemotherapy treatment 2
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 482
- Registration Number
- NCT07079631
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 550
- Registration Number
- NCT07070232
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Adults, Including Those at Higher Risk of Severe COVID-19
- Conditions
- COVID-19SARS-COV-2 Infection
- Interventions
- Biological: BNT162b2 (Omi LP.8.1)
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 100
- Registration Number
- NCT07069309
- Locations
- 🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States
🇺🇸Indago Research & Health Center, Inc, Hialeah, Florida, United States
🇺🇸Bio-Kinetic Clinical Applications, LLC dba QPS-MO, Springfield, Missouri, United States
A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm
- Conditions
- Testicular Germ Cell TumorExtragonadal Germ Cell Tumor
- Interventions
- Biological: CLDN6 CAR-T
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 150
- Registration Number
- NCT06940804
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next
News
HHS Halts Vaxart's $460 Million Oral COVID-19 Vaccine Trial Amid Federal mRNA Program Rollback
The Department of Health and Human Services issued a stop work order on August 5, 2025, halting Vaxart's Phase IIb trial for VXA-CoV2-3.3, an oral COVID-19 vaccine that had enrolled approximately 5,000 of its targeted 10,000 participants.
IO Biotech's Melanoma Vaccine Narrowly Misses Primary Endpoint in Phase 3 Trial Despite Promising Subgroup Results
IO Biotech's cancer vaccine Cylembio combined with Keytruda showed a 23% relative risk reduction in disease progression or death compared to Keytruda alone, but narrowly missed statistical significance with a p-value of 0.056.
GSK Secures $370 Million Settlement and Future Royalties in CureVac-BioNTech mRNA Patent Dispute
GSK will receive $370 million upfront from CureVac following a patent settlement involving BioNTech and Pfizer over mRNA vaccine technology, with $320 million paid in cash.
OncoC4's ONC-841 Shows Promise as First-in-Class Alzheimer's Disease Immunotherapy in Preclinical Studies
OncoC4 unveiled preclinical data showing ONC-841, a first-in-class anti-SIGLEC 10 monoclonal antibody, reduced amyloid plaques and improved memory in Alzheimer's disease mouse models.
Bristol Myers Squibb Appoints AstraZeneca's Cristian Massacesi as New Chief Medical Officer
Bristol Myers Squibb has appointed Cristian Massacesi, M.D., former AstraZeneca Chief Medical Officer, as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025.
EU Regulatory Approval Advances Pfizer-BioNTech LP.8.1-Adapted COVID-19 Vaccine for 2025-2026 Season
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Pfizer and BioNTech's LP.8.1-adapted COMIRNATY vaccine targeting XFG and NB.1.8.1 variants.
Turkish Study Links Pfizer COVID-19 Vaccine to Corneal Structural Changes
A Turkish study of 64 patients found measurable corneal changes 75 days after receiving two doses of the Pfizer-BioNTech COVID-19 vaccine, including 2% increased thickness and 8% reduced endothelial cell density.
BioNTech Chief Strategy Officer Ryan Richardson to Step Down After Seven-Year Tenure
Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.
Regeneron and BioNTech Advance Phase 2 Trial Combining Cancer Vaccine BNT116 with Cemiplimab for Advanced NSCLC
Regeneron Pharmaceuticals and BioNTech SE are conducting a Phase 2 clinical trial evaluating the combination of investigational cancer vaccine BNT116 with cemiplimab versus cemiplimab monotherapy in advanced non-small cell lung cancer patients with PD-L1 expression ≥50%.
Genmab and BioNTech Advance Two Phase 1/2 Cancer Trials Testing Novel Antibody Therapies
Genmab and BioNTech are conducting two separate clinical trials evaluating novel antibody therapies for solid tumors, including GEN1055 monotherapy and combination treatments.